文献速递姑息放疗与转移瘤

姑息性放疗剂量对转移性肉瘤症状缓解的影响

Effect of palliative radiation dose on symptom response in metastatic sarcomas.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-06-07

本研究回顾性分析1999至2021年间在本机构接受姑息性放疗的转移性肉瘤患者,评估生物有效剂量(EQD2,α/β=3)与症状缓解及总生存的关系。结果显示EQD2>20 Gy组短期症状缓解率高于EQD2≤20 Gy组(85% vs 54%,P=0.001),但更高剂量未进一步改善缓解;多因素分析中EQD2与总生存无显著差异。作者认为EQD2≤20 Gy(如8 Gy单次)姑息获益不足,而20 Gy分5次(EQD2=28 Gy)等标准方案有效。

要点

  • EQD2>20 Gy组短期症状缓解率85%,高于EQD2≤20 Gy组的54%(P=0.001)。
  • 更高放疗剂量未进一步改善短期症状缓解或持久性。
  • 多因素分析中EQD2与总生存无显著差异,未见3级及以上毒性报告。

核心结论

  • EQD2≤20 Gy(如8 Gy单次)在本系列中姑息获益不足。
  • EQD2>20 Gy使转移性肉瘤症状缓解率更高,但进一步剂量提升未改善症状缓解或持久性。
  • 作者认为20 Gy分5次(EQD2=28 Gy)等标准姑息方案对转移性肉瘤患者有效。

研究设计与样本

  • 回顾性识别1999至2021年在本机构接受姑息性放疗的转移性肉瘤患者。
  • 分析EQD2(α/β=3)与症状缓解及总生存的关联,采用单因素和多因素分析。
  • 共治疗198个转移部位。

主要发现

  • 姑息放疗最常见指征为疼痛(n=181,91%)和邻近结构压迫(n=16,8%)。
  • EQD2>20 Gy组短期症状缓解率85%(n=143),EQD2≤20 Gy组54%(n=14),P=0.001。
  • 更高放疗剂量未显著改善短期症状缓解。
  • EQD2≤20 Gy组体能状态显著更差。
  • 多因素分析中EQD2与总生存无显著差异。

关键数值与推荐

  • EQD2>20 Gy与EQD2≤20 Gy相比短期症状缓解率更高(85% vs 54%,P=0.001)。
  • EQD2≤20 Gy(如8 Gy单次)在本系列中姑息获益不足。
  • 20 Gy分5次对应EQD2=28 Gy。

临床怎么用

  • 作者认为20 Gy分5次(EQD2=28 Gy)等标准姑息方案对转移性肉瘤患者有效。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Palliative radiotherapy (RT) plays a crucial role in alleviating symptoms associated with metastatic sarcoma. However, there is a lack of consensus on the optimal palliative radiation dose and fractionation for metastatic sarcomas. We analyzed the association between biologically effective radiation dose and symptom response for patients who underwent palliative RT for metastatic sarcomas. METHODS AND MATERIALS: We retrospectively identified patients with metastatic sarcoma treated with palliative RT between 1999 and 2021 at our institution. We assessed the association between equivalent dose in 2 Gy fractions (EQD2) with an α/β of three and symptom relief or overall survival (OS) using univariable and multivariable analyses. RESULTS: Of the 198 metastatic sites treated, the most common indications for palliative radiation were pain (n = 181, 91 %) and compression of adjacent structures (n = 16, 8 %). In our analysis, an EQD2 of > 20 Gy was associated with greater rates of short-term symptom relief (n = 143, 85 %) at the RT site compared to an EQD2 of ≤ 20 Gy (n = 14, 54 %, P = 0.001) with no reports of grade 3 or higher toxicity. However, there was no significant improvement in short-term symptom relief for higher radiation doses. Patients treated with an EQD2 of ≤ 20 Gy had a significantly worse performance status, but there was no significant difference in overall survival based on EQD2 on multivariable analysis. CONCLUSIONS: An EQD2 ≤ 20 Gy (e.g., 8 Gy in 1 fraction) provided inadequate palliative benefit in this series. An EQD2 > 20 Gy resulted in greater rates of symptom palliation in metastatic sarcomas, but further dose escalation did not improve symptom response or durability. These findings suggest standard palliative regimens such as 20 Gy in 5 fractions (EQD2 of 28 Gy) are effective for patients with metastatic sarcomas.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Matsui JK, Jackson S, Fang J, et al. Effect of palliative radiation dose on symptom response in metastatic sarcomas. Clin Transl Radiat Oncol. 2024. PMID: 38988806. doi:10.1016/j.ctro.2024.100803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。